Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 609A plus doxorubicin in metastatic or unresectable unspecified soft tissue sarcoma
CTR20212888Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 609A, doxorubicin in soft tissue sarcoma (STS), sponsored by 3S Guojian Pharmaceutical. Started Nov 2021; status: active.
02
Drugs
609Adoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20212888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212888.